Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Stephen Stahl

Carlsbad, CA Medical Doctor

NPI 1710144167 CMS profile 77110

1930 Palomar Point Way, Suite 103, Carlsbad, CA 92008

Open in the dashboard

General payments

$1,409,281

398 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Stephen Stahl of Carlsbad, CA is reported in the CMS Open Payments database as having received $1,409,281 across 398 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $28,865 18
2024 General $47,980 39
2023 General $106,776 84
2022 General $46,858 24
2021 General $91,330 35
2020 General $543,332 65
2019 General $544,141 133

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stephen Stahl
  • California median
  • Middle half of California
  • National median

In program year 2025, general payments to Stephen Stahl were reported at $28,865. Among 98,626 California profiles paid that year, the median was $172 and the middle half received between $54 and $610.

Show as a table
Year Stephen Stahl California median Middle half National median
2019 $544,141 $161 $50–$652 $163
2020 $543,332 $114 $34–$392 $114
2021 $91,330 $137 $41–$509 $132
2022 $46,858 $152 $48–$573 $149
2023 $106,776 $162 $50–$581 $160
2024 $47,980 $162 $52–$583 $164
2025 $28,865 $172 $54–$610 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Sunovion Pharmaceuticals Inc. $435,246 37 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $382,230 8 payments
  3. H. Lundbeck A S $72,212 24 payments
  4. ITI, Inc. $66,316 58 payments
  5. Alkermes, Inc. $60,365 40 payments
  6. ACADIA Pharmaceuticals Inc $58,629 50 payments
  7. AbbVie, Inc. $46,866 39 payments
  8. Teva Pharmaceuticals USA, Inc. $42,856 16 payments
  9. Allergan Inc. $35,328 20 payments
  10. E.R. Squibb & Sons, L.L.C. $28,829 14 payments
  11. Other $180,404 92 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $611,171 67 payments
  2. Grant $379,008 4 payments
  3. Consulting Fee $253,565 91 payments
  4. Honoraria $82,226 22 payments
  5. Travel and Lodging $75,779 131 payments
  6. Food and Beverage $7,408 78 payments
  7. Education $124 5 payments
Products named General payments · program years 2019–2025
  1. Trintellix $295,470 5 payments
  2. LATUDA $208,810 29 payments
  3. SEP-225289 $200,000 1 payment
  4. CAPLYTA $66,316 58 payments
  5. BRINTELLIX $61,077 17 payments
  6. VRAYLAR Neuroscience $46,866 39 payments
  7. NUPLAZID $46,579 42 payments
  8. AUSTEDO $42,767 15 payments
  9. VRAYLAR Neuroscience $35,328 20 payments
  10. REXULTI $32,772 13 payments
  11. Other $246,600 156 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

398 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record